Open AccessCurrent Perspectives on the Systemic Management of Atopic Dermatitis
Author(s) -
Danielle R. Davari,
Elizabeth L. Nieman,
Diana B. McShane,
Dean S. Morrell
Publication year - 2021
Publication title -
journal of asthma and allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.162
H-Index - 30
ISSN - 1178-6965
DOI - 10.2147/jaa.s287638
Subject(s) - medicine , dupilumab , atopic dermatitis , methotrexate , azathioprine , dermatology , mycophenolate , disease , intensive care medicine , immunology , transplantation
Atopic dermatitis (AD) is a common disease of childhood, and some patients experience a prolonged clinical course into adolescence and adulthood. Systemic management is required when AD is not adequately controlled with topical medications. Our aim is to provide a comprehensive review of commonly used systemic immunomodulating agents in childhood and adult AD, including cyclosporine A (CsA), azathioprine (AZA), methotrexate (MTX) and mycophenolate mofetil (MMF), which are prescribed off-label in the United States, as well as dupilumab, an FDA-approved biologic. We will also provide a brief overview of emerging systemic therapies currently under investigation.